Evidence map›Paper›PMID 39913242›Full record

ArticleThe Journal of infectious diseases2025

Is Systemic Dissemination of BCG Following Neonatal Vaccination Required for Protection Against Mycobacterium tuberculosis?

Tobias R Kollmann, Nelly Amenyogbe, Frederik Schaltz-Buchholzer, Ole Bæk, James Campbell, David J Lynn, Anita J Campbell, Peter Aaby, Christine Stabell Benn, Mihai G Netea and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Route of BCG administration determines success.Human vaccines & immunotherapeutics · 2026
    Review
  2. Review
  3. The BCGMethodsX · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tobias R KollmannCanadian Center for Vaccinology, IWK, Dalhousie University, Halifax, Nova Scotia, Canada.ORCID 0000-0003-2403-9762
Nelly AmenyogbeCanadian Center for Vaccinology, IWK, Dalhousie University, Halifax, Nova Scotia, Canada.
Frederik Schaltz-BuchholzerBandim Health Project, INDEPTH Network, Bissau, Guinea-Bissau.ORCID 0000-0001-7643-8322
Ole BækComparative Pediatrics and Nutrition.
James CampbellCentral Perth Skin Clinic, Perth, Western Australia, Australia.
David J LynnPrecision Medicine, South Australian Health and Medical Research Institute, Adelaide, South Australia.ORCID 0000-0003-4664-1404
Anita J CampbellInfectious Diseases Department, Perth Children's Hospital, Perth.ORCID 0000-0002-5898-1126
Peter AabyBandim Health Project, INDEPTH Network, Bissau, Guinea-Bissau.ORCID 0000-0001-8331-1389
Christine Stabell BennBandim Health Project, Odense Patient Data Explorative Network, Department of Clinical Research, Odense University Hospital.ORCID 0000-0001-6102-3810
Mihai G NeteaDepartment of Internal Medicine and Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.
Maziar DivangahiDepartments of Medicine, Pathology, and Microbiology & Immunology, McGill University Health Centre, McGill International Tuberculosis Centre, Meakins Christie Laboratories, McGill University, Montreal, Quebec, Canada.

Funding

Transcriptomics to define biomarkers of neonatal vaccine immunogenicityU19AI118608 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI LEVY, OFER · 2017 to 2021
$24.7M
Proteomics and Metabolomics Core: IDEAL shapes vaccine response, susceptibility to respiratory infectious disease and asthmaU19AI168643 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI OFER LEVY · 2022 to 2026
$10.0M
Targeting trained immunity and Th1/Th17 axis with combination adjuvantsU01AI160406 · NIAID · WASHINGTON UNIVERSITY · PI DIVANGAHI, MAZIAR, KAUSHAL, DEEPAK · 2021 to 2025
$3.0M
Australian National Health and Medical Research CouncilBRIDGE-Translational Excellence ProgrammeCIHR 168885CIHR 503114Dalhousie UniversityFaculty of Health and Medical Sciences, University of CopenhagenGates Foundation INV-003360National Institute of Allergy and Infectious Diseases U19AI118608National Institute of Allergy and Infectious Diseases U19AI168643National Institutes of Health (NIH)NIAID NIH HHS U01 AI160406NIAID NIH HHS U19 AI118608NIAID NIH HHS U19 AI168643NIH HHS (grant number U01-AI160406)Novo Nordisk FoundationNovo Nordisk Foundation NNF23SA0087869 andOpen PhilanthropyRaine Clinician Research FellowshipSouth Australian Department of Health
6 · The paper itself

Abstract

Tuberculosis (TB) is caused by Mycobacterium tuberculosis (Mtb) and is a leading cause of death. BCG is the only licensed TB vaccine. Preclinical studies have shown that in adults, intravenous administration of BCG improves protection against TB. We hypothesize that intradermal administration of BCG to the human newborn leads to low-grade BCG bacteremia and that this systemic dissemination improves protection against Mtb infection. This hypothesis is based on supporting observations including animal and human studies. It is a testable hypothesis and offers to deliver immediately actionable insight to advance the global efforts against TB.

Indexed as

BacteremiaBCG VaccineMycobacterium tuberculosisTuberculosisAnimalsHumansInfant, NewbornVaccinationBCG VaccineadultbacteremiaBCGneonateTB

Identifiers

PMID39913242
PMCPMC12247822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.